Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Javier CortesHope S RugoDavid W CesconSeock-Ah ImMastura M YusofCarlos GallardoOleg LipatovCarlos H BarriosJose Perez-GarciaHiroji IwataNorikazu MasudaMarco Torregroza OteroErhan GokmenSherene LoiZifang GuoXuan ZhouVassiliki KarantzaWilbur PanPeter Schmidnull nullPublished in: The New England journal of medicine (2022)
Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone. (Funded by Merck Sharp and Dohme; KEYNOTE-355 ClinicalTrials.gov number, NCT02819518.).